Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Jul 28, 2014 (12 years ago)

OXYCODONE HYDROCHLORIDE C II Oral Solution USP

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Stability Specifications: Out of specification result for preservative sodium benzoate.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

OXYCODONE HYDROCHLORIDE C II Oral Solution USP, 5 mg/5 mL, 15 mL Vial, Rx only. Boehringer Ingelheim, Roxane Laboratories. Roxane Laboratories, Inc. Columbus, Ohio 43216. NDC: 0054-0523-41.

Affected NDC 0054-0523-41

Compare with the code on your package — it is the most precise check available.

Drug: Oxycodone

Recalling firm
Boehringer Ingelheim Roxane Inc
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1486-2014 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Oxycodone recalls

See all
Class II · Moderate risk

Oxycodone Hydrochloride Tablets

Defective container: card seal defects (weak/non-existent seals), leading to the tablets falling out of their cavities.

Ongoing Packaging defect Amerisource Health Services LLC NDC 68084-354-01 D-0338-2026

Other recalls by Boehringer Ingelheim Roxane Inc

All 2014 recalls
Class III · Low risk

FUROSEMIDE Tablets USP

CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral solution USP was inadvertently used to manufacture the recalled furosemide tablets USP.

Terminated cGMP deviation Boehringer Ingelheim Roxane Inc NDC 0054-4299-31 D-0012-2016
Class III · Low risk

FUROSEMIDE Tablets USP

CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral solution USP was inadvertently used to manufacture the recalled furosemide tablets USP.

Terminated cGMP deviation Boehringer Ingelheim Roxane Inc NDC 0054-4297-31 D-0011-2016
Class II · Moderate risk

Combivent Respimat

Defective Delivery System: Inhalers do not spray properly, emitting either no spray or a short transient spray.

Terminated Packaging defect Boehringer Ingelheim Roxane Inc NDC 0597-0024-02 D-1279-2015